Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E2F transcription factor 7 (E2F7) is an atypical member of the E2F family of transcription factors that primarily functions as a transcriptional repressor of cell cycle progression and DNA repair genes[1][3][4][6]. Unlike canonical E2F proteins, E2F7 contains two distinct DNA-binding domains and binds DNA independently of DP co-factors, preferentially associating with a subset of E2F-responsive gene promoters. It regulates transcription by directly repressing genes required for cell cycle transition (notably at G1/S), DNA replication, and DNA repair, thus integrating cell cycle control with the DNA damage response and maintenance of genomic integrity[4][5]. E2F7 also plays roles in angiogenesis and cellular polyploidization. Its aberrant expression or activity can contribute to oncogenesis, as it modulates pathways implicated in cancer and cell survival[1][4][5][6]. No drugs are currently known to specifically target E2F7.
Transcriptional repression of E2F target genes via direct DNA binding; inhibition of cell cycle progression; repression of DNA repair gene expression[1][4][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E2F transcription factor 7 (E2F7).